Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $98.00. The ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The ...

it appears that whales have been targeting a price range from $70.0 to $125.0 for DexCom over the last 3 months. Insights into Volume & Open Interest In today's trading context, the average open ...

Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of DexCom in a research note issued to ...

DexCom (NASDAQ:DXCM – Get Free Report) had its price target increased by equities researchers at Citigroup from $101.00 to $104.00 in a note issued to investors on Tuesday,Benzinga reports.

The recent selloff of U.S. equities continued at midday on fears the U.S. economy could be heading toward a recession. The Nasdaq sank 3%, the S&P 500 dipped about 2%, and the Dow Jones Industrial ...

DexCom's growth is slowing ... The valuation of DXCM at 43x non-GAAP forward P/E and 7.5x forward price to sales does not adequately factor in these emerging risks. Given the current competitive ...

Insulet (Nasdaq:PODD) announced today that it made its Omnipod 5 automated insulin delivery system available in several new ...

BofA keeps a Buy rating on DexCom (DXCM) with a $105 price target after Dexcom announced it received a warning letter from the FDA. Importantly, ...